Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Medtronic
AstraZeneca
Boehringer Ingelheim

Last Updated: May 24, 2022

CLINICAL TRIALS PROFILE FOR SIBUTRAMINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Sibutramine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00037752 ↗ Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2002-09-01 The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.
NCT00037752 ↗ Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates Completed University of Tennessee N/A 2002-09-01 The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.
NCT00044187 ↗ The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed Eli Lilly and Company Phase 4 2001-04-01 Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.
NCT00134199 ↗ A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects Completed Pfizer Phase 2/Phase 3 2005-03-01 To evaluate the effect of 6-month administration of CP-945,598 on: - weight loss and waist circumference, - blood pressure, cholesterol, glucose - other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP - the relationship between the concentration of the drug on the blood and the above parameters - physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression
NCT00212173 ↗ Adolescent Weight Management Study Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 1969-12-31 Protocol #1:The goals of this study was to examine whether increased weight loss in obese adolescent is induced when the weight loss medication sibutramine is added to a family-based, behavioral weight control program. Protocol #2: This study aims to improve the behavioral treatment of obesity during adolescence. A behavioral program using regular foods will be compared to a behavioral program using a structured meal plan (a portion-controlled approach with liquid-meal replacements [nutritional supplements]). This structured approach may be better for the promotion of weight loss compared to a diet of regular foods.
NCT00221442 ↗ Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed Eisai Inc. Phase 3 2005-08-01 The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sibutramine Hydrochloride

Condition Name

Condition Name for Sibutramine Hydrochloride
Intervention Trials
Obesity 28
Overweight 4
Vasovagal Syncope 3
Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sibutramine Hydrochloride
Intervention Trials
Obesity 10
Overweight 9
Weight Loss 9
Bulimia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sibutramine Hydrochloride

Trials by Country

Trials by Country for Sibutramine Hydrochloride
Location Trials
United States 82
Canada 2
Greece 2
Korea, Republic of 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sibutramine Hydrochloride
Location Trials
Florida 6
Texas 6
New York 6
California 5
Minnesota 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sibutramine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Sibutramine Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sibutramine Hydrochloride
Clinical Trial Phase Trials
Completed 27
Terminated 5
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sibutramine Hydrochloride

Sponsor Name

Sponsor Name for Sibutramine Hydrochloride
Sponsor Trials
Abbott 7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
University of Calgary 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sibutramine Hydrochloride
Sponsor Trials
Industry 21
Other 20
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Baxter
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.